The new study, which was published July 5 in an advanced, online edition of the Proceedings of the National Academy of Sciences, achieved a significant enhancement of the treatment of metastatic breast cancer in animal models. The study showed the new hybrid compound remained in circulation for a week. In comparison, the small molecule drug was cleared in a matter of minutes.
